Backgrounder
*Updated: September, 1996
Prepared by:
Kimberly Struble
Heidi Marchand
Richard Klein
Office of AIDS and Special Issues
Food and Drug Administration
Division of Antiviral Drug Products
Food and Drug Administration
Under dosing, noncompliance, or partial-compliance with dosing regimens for these drugs may result in development of a resistant strain(s) of HIV that will not be susceptible to treatment with protease inhibitors. Patients must be aware of the need to take the complete dose to lessen the risk of potential drug resistance. Patients should not modify the dosage in any way to "extend" their prescription.
The protease inhibitors are partially metabolized by the cytochrome P450 oxidase system and have a potential for serious interactions with a large number of commonly prescribed drug products metabolized by the same pathway.
The following tables profile the similarities and differences of each approved protease inhibitor, and provide useful information about dosing storage, potential drug interactions, and therapeutic options.
* Updated information is highlighted with italics
Go to the Protease Inhibitor Menu
Go to the HIVpositive.us Main Menu
39